Question: is this a 2) strong advice, 1) weak advice 0) no advice?

In two randomized trials comparing the PCSK9 inhibitor bococizumab with placebo, bococizumab had no benefit with respect to major adverse cardiovascular events in the trial involving lower-risk patients but did have a significant benefit in the trial involving higher-risk patients.
user
This is no advice
assistant